. De-la-masse-sèche, Ce sont des pigments responsables de la coloration des fleurs et des fruits

A. R. Bilia, Structure générale des flavonoïdes, Figure, vol.14, 2002.

Ø. Hyperine, Hyperoside) 0,7% dans la plante fraîche, Ø Rutine (Rutoside) 0,3% dans la plante fraîche, p.3

. Généralement, hyperoside et le rutoside sont les deux sucres les plus présents dans la plante

L. Andrén, A. Andreasson, and R. Eggertsen, Interaction between a commercially available St. John???s wort product (Movina) and atorvastatin in patients with hypercholesterolemia, European Journal of Clinical Pharmacology, vol.352, issue.14, pp.63-913, 2007.
DOI : 10.1007/s00228-007-0345-x

K. H. Baureithel, K. B. Buter, A. Engesser, W. Burkard, and W. Schaffner, Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum, Pharmaceutica Acta Helvetiae, vol.72, issue.3, pp.153-157, 1997.
DOI : 10.1016/S0031-6865(97)00002-2

R. Bedry and E. Sudre, Le syndrome sérotoninergique, Le Praticien en Anesthésie Réanimation, pp.278-282, 2009.

A. R. Bilia, S. Gallori, and F. F. Vincieri, St. John's wort and depression, Life Sciences, vol.70, issue.26, pp.3077-3096, 2002.
DOI : 10.1016/S0024-3205(02)01566-7

URL : https://hal.archives-ouvertes.fr/hal-00573866

F. Borrelli and A. A. Izzo, Herb???Drug Interactions with St John???s Wort (Hypericum perforatum): an Update on Clinical Observations, The AAPS Journal, vol.11, issue.4, pp.11-710, 2009.
DOI : 10.1208/s12248-009-9146-8

M. Botineau, Botanique systématique et appliquée des plantes à fleur, 2010.

A. Bouron and E. Lorrain, Effets cellulaires et mol??culaires de l???hyperforine, un antid??presseur v??g??tal??: revue de la litt??rature, L'Enc??phale, vol.40, issue.2, pp.1-6, 2013.
DOI : 10.1016/j.encep.2013.03.004

R. Brenner, V. Azbel, S. Madhusoodanan, and M. Pawlowska, Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study, Clinical Therapeutics, vol.22, issue.4, pp.411-419, 2000.
DOI : 10.1016/S0149-2918(00)89010-4

D. Briese, M. Campbell, and I. Faithfull, St John's Wort, hypericum perforatum, Best practice management guide, pp.1-6, 2000.

J. Bruneton, Plantes toxiques : Végétaux dangereux pour l'homme et les animaux, 2001.

J. Bruneton, Les données de l'évolution, 2002.

J. Bruneton, Pharmacognosie, phytochimie, plantes médicinales, Paris, 4 ème édition, 2009.

C. Busser and E. Et, Les plantes des Vosges Médecine et traditions populaires, 2005.

V. Butterweck, Mechanism of Action of St John???s Wort in Depression, CNS Drugs, vol.3, issue.3, pp.539-562, 2003.
DOI : 10.2165/00023210-200317080-00001

V. Butterweck, A. Nahrstedt, J. Evans, S. Hufeisen, L. Rauser et al., In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs, Psychopharmacology, vol.162, issue.2, pp.162-193, 2002.
DOI : 10.1007/s00213-002-1073-7

S. Caccia and M. Gobbi, St. Johns Wort Components and the Brain: Uptake, Concentrations Reached and the Mechanisms Underlying Pharmacological Effects, Current Drug Metabolism, vol.10, issue.9, pp.1055-1065, 2009.
DOI : 10.2174/138920009790711878

URL : https://hal.archives-ouvertes.fr/hal-00329183

Y. Chen, S. Ferguson, M. Negishi, and J. Goldstein, Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor, Journal of Pharmacology and Experimental Therapeutics, vol.308, issue.2, pp.495-501, 2003.
DOI : 10.1124/jpet.103.058818

A. Daovy, Le millepertuis, Actualités pharmaceutiques, pp.45-47, 2008.

D. Maat, M. M. Hoetelmans, R. M. Math-t, R. Van-gorp, E. Meenhorst et al., Drug interaction between St John's wort and nevirapine, AIDS, issue.3, pp.15-420, 2001.

G. K. Dresser, U. I. Schwarz, G. R. Wilkinson, and R. B. Kim, Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects, Clinical Pharmacology & Therapeutics, vol.73, issue.1, pp.41-50, 2003.
DOI : 10.1067/mcp.2003.10

J. J. Dugoua, E. Mills, D. Perri, and G. Koren, Safety and efficacy of St John's Wort (Hypericum) during pregnancy and lactation, The Canadian Journal of Clinical Pharmacology, vol.13, issue.3, pp.268-276, 2006.

M. Fava, J. Alper, A. A. Nierenberg, D. Mischoulon, M. W. Otto et al., A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder, Journal of Clinical Psychopharmacology, vol.25, issue.5, pp.441-447, 2005.
DOI : 10.1097/01.jcp.0000178416.60426.29

G. Garnier, L. Bézanger-beauquesne, and G. Debraux, Ressources médicinales de la flore française, 1961.

M. Gastpar, A. Singer, and K. Zeller, Efficacy and Tolerability of Hypericum Extract STW3 in Long-term Treatment with a Once-daily Dosage in Comparison with Sertraline, Pharmacopsychiatry, vol.38, issue.2, pp.78-86, 2005.
DOI : 10.1055/s-2005-837807

M. Gastpar, A. Singer, and K. Zeller, Comparative Efficacy and Safety of a Once-Daily Dosage of Hypericum Extract STW3-VI and Citalopram in Patients with Moderate Depression: A Double-Blind, Randomised, Multicentre, Placebo-Controlled Study, Pharmacopsychiatry, vol.39, issue.2, pp.66-75, 2006.
DOI : 10.1055/s-2006-931544

M. Gobbi, M. Moia, M. Funicello, A. Riva, P. Morazzoni et al., Effects of the Dicyclohexylammonium Salt of Hyperforin on Interleukin-6 Release in Different Experimental Models, Planta Medica, vol.70, issue.7, pp.680-682, 2004.
DOI : 10.1055/s-2004-827194

J. M. Greeson, B. Sanford, and D. A. Monti, St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature, Psychopharmacology, vol.153, issue.4, pp.403-414, 2001.
DOI : 10.1007/s002130000625

B. Gregoretti, M. Stebel, L. Candussio, E. Crivellato, F. Bartoli et al., Toxicity of Hypericum perforatum (St. John's wort) administered during pregnancy and lactation in rats, Toxicology and Applied Pharmacology, vol.200, issue.3, pp.201-205, 2004.
DOI : 10.1016/j.taap.2004.04.020

T. N. Griffith, L. Varela-nallar, M. C. Dinamarca, and N. C. Inestrosa, Neurobiological Effects of Hyperforin and its Potential in Alzheimers Disease Therapy, Current Medicinal Chemistry, vol.17, issue.5, pp.391-406, 2010.
DOI : 10.2174/092986710790226156

B. Gurley, A. Swain, D. Williams, G. Barone, and S. Battu, Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: Comparative effects of St, 2008.

B. J. Gurley, S. F. Gardner, M. A. Hubbard, D. K. Williams, W. B. Gentry et al., Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans*, Clinical Pharmacology & Therapeutics, vol.72, issue.3, pp.72-276, 2002.
DOI : 10.1067/mcp.2002.126913

K. D. Hammer, M. Yuma, P. M. Dixon, and D. F. Birt, Identification of JAK?STAT pathways as important for the anti-inflammatory activity of a Hypericum perforatum fraction and bioactive constituents in RAW 264, Phytochemistry, issue.7, pp.71-716, 2010.

P. D. Hansten and J. R. Horn, The top 100 drug interactions: A Guide to Patient Management, 2014.

. St, John's wort extract LoHyp-57 and fluoxetine, Arzneimittelforschung, vol.49, pp.289-296

M. F. Hebert, J. M. Park, Y. L. Chen, S. Akhtar, and A. M. Larson, ) on Tacrolimus Pharmacokinetics in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.97, issue.1, pp.89-94, 2004.
DOI : 10.1177/0091270003261078

J. H. Heiser, A. M. Schuwald, G. Sillani, L. Ye, W. E. Müller et al., TRPC6 channel-mediated neurite outgrowth in PC12 cells and hippocampal neurons involves activation of RAS/MEK/ERK, PI3K, and CAMKIV signaling, PI3K, and CAMKIV signaling, pp.303-313, 2013.
DOI : 10.1111/jnc.12376

J. Hokkanen, A. Tolonena, S. Mattilab, and M. Turpeinena, Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes, European Journal of Pharmaceutical Sciences, vol.42, issue.3, pp.42-273, 2011.
DOI : 10.1016/j.ejps.2010.12.002

Z. P. Hu, X. X. Yang, S. Y. Chan, A. L. Xu, W. Duan et al., St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis, Toxicology and Applied Pharmacology, vol.216, issue.2, pp.225-237, 2006.
DOI : 10.1016/j.taap.2006.05.020

URL : https://hal.archives-ouvertes.fr/hal-00406976

N. Huang, L. Rizshsky, C. Hauck, B. J. Nikolau, P. A. Murphy et al., Identification of anti-inflammatory constituents in Hypericum perforatum and Hypericum gentianoides extracts using RAW 264, Phytochemistry, issue.16, p.72, 2011.

H. Imai, T. Kotegawa, K. Tsutsumi, T. Morimoto, N. Eshima et al., The recovery time-course of CYP3A after induction by St John's wort administration, British Journal of Clinical Pharmacology, vol.31, issue.5, pp.65-701, 2008.
DOI : 10.1211/0022357011775974

I. F. Benzie and S. Wachtel-galor, Herbal Medicine, 2011.
DOI : 10.1201/b10787-2

A. A. Izzo and E. Ernst, Interactions between herbal medicines and prescribed drugs. An update systematic review, Drugs, issue.13, pp.69-1777, 2009.

X. Jiang, K. M. Williams, W. S. Liauw, A. J. Ammit, B. D. Roufogalis et al., Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects, British Journal of Clinical Pharmacology, vol.990, issue.5, pp.592-599, 2004.
DOI : 10.1016/S0378-8741(02)00317-3

R. Kalb, R. D. Trautmann-sponsel, and M. Kieser, Efficacy and Tolerability of Hypericum Extract WS 5572 versus Placebo in Mildly to Moderately Depressed Patients - A randomized double-blind multicenter clinical trial -, Pharmacopsychiatry, vol.34, issue.3, pp.96-103, 2001.
DOI : 10.1055/s-2001-14280

S. John-'s, Wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial, BMC Medicine, p.14

S. Kasper, F. Caraci, B. Forti, F. Drago, and E. Aguglia, Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression, European Neuropsychopharmacology, vol.20, issue.11, pp.747-765, 2010.
DOI : 10.1016/j.euroneuro.2010.07.005

S. Kasper, M. Gastpar, W. E. Müller, H. P. Volz, A. Dienel et al., Efficacy of St. John???s wort extract WS?? 5570 in acute treatment of mild depression, European Archives of Psychiatry and Clinical Neuroscience, vol.10, issue.Suppl 1, pp.59-63, 2008.
DOI : 10.1007/s00406-007-0779-2

A. Kawaguchi, M. Ohmori, S. Tsuruoka, K. Nishiki, K. Harada et al., Drug interaction between St John's Wort and quazepam, British Journal of Clinical Pharmacology, vol.5, issue.4, pp.403-410, 2004.
DOI : 10.1046/j.1365-2125.2002.01683.x

M. Kober, K. Pohl, and T. Efferth, Molecular Mechanisms Underlying St. Johns Wort Drug Interactions, Current Drug Metabolism, vol.9, issue.10, pp.1027-1037, 2008.
DOI : 10.2174/138920008786927767

J. M. Koch, S. Kell, D. Hinze-selch, and J. B. Aldenhoff, Changes in CREB-phosphorylation during recovery from major depression, Changes in CREBphosphorylation during recovery from major depression, pp.369-375, 2002.
DOI : 10.1016/S0022-3956(02)00056-0

G. Laakmann, C. Schule, T. Baghai, and M. Kieser, St. John's Wort in Mild to Moderate Depression: The Relevance of Hyperforin for the Clinical Efficacy, Pharmacopsychiatry, vol.31, issue.S 1, pp.31-54, 1998.
DOI : 10.1055/s-2007-979346

Y. Lecrubier, G. Clerc, R. Didi, and M. Kieser, Efficacy of St. John's wort extract WS?? 5570 in major depression ??? a double-blind, placebo-controlled trial, European Psychiatry, vol.17, pp.1361-1366, 2002.
DOI : 10.1016/S0924-9338(02)80310-8

A. Lee, R. Minhas, N. Matsuda, M. Lam, and S. Ito, ) During Breastfeeding, The Journal of Clinical Psychiatry, vol.64, issue.8, pp.966-968, 2003.
DOI : 10.4088/JCP.v64n0818

. Hyperforin, . Key, and . St, John's wort specifically activates TRPC6 channels, FASEB Journal, vol.21, issue.14, pp.4101-4111

K. Linde, M. Berner, and L. Kriston, St John's wort for major depression, The Cochrane Library, pp.1-103, 2008.

K. Linde and L. Knüppel, Large-scale observational studies of hypericum extracts in patients with depressive disorders???a systematic review, Phytomedicine, vol.12, issue.1-2, pp.148-57, 2005.
DOI : 10.1016/j.phymed.2004.02.004

K. Linde, St John's Wort -an Overview, Forsch Komplementmed, vol.16, issue.3, pp.146-155, 2009.

I. Mai, S. Bauer, E. S. Perloff, A. Johne, B. Uehleke et al., Hyperforin content determines the magnitude of the St John's wort???cyclosporine drug interaction, Clinical Pharmacology & Therapeutics, vol.76, issue.4, pp.330-340, 2004.
DOI : 10.1016/j.clpt.2004.07.004

I. Mai, E. Störmer, S. Bauer, H. Krüger, K. Budde et al., Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients, Nephrology Dialysis Transplantation, vol.18, issue.4, pp.819-822, 2003.
DOI : 10.1093/ndt/gfg002

J. S. Markowitz, J. L. Donovan, C. L. Devane, R. M. Taylor, Y. Ruan et al., Effect of St John's Wort on Drug Metabolism by Induction of Cytochrome P450 3A4 Enzyme, JAMA, vol.290, issue.11, pp.290-1500, 2003.
DOI : 10.1001/jama.290.11.1500

J. C. Milton and A. Abdulla, Prolonged oro-facial dystonia in a 58??year old female following therapy with bupropion and St John's Wort, British Journal of Clinical Pharmacology, vol.64, issue.5, pp.717-725, 2007.
DOI : 10.1046/j.0306-5251.2001.01469.x

L. B. Moore, B. Goodwin, S. A. Jones, G. B. Wisely, C. J. Serabjit-singh et al., St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor, Proceedings of the National Academy of Sciences of the USA, pp.7500-7502, 2000.
DOI : 10.1073/pnas.130155097

R. A. Moreno, C. Teng, K. Almeida, T. Junior, and H. , Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample, Revista Brasileira de Psiquiatria, vol.28, issue.1, pp.29-32, 2006.
DOI : 10.1590/S1516-44462006000100007

M. E. Moretti, A. Maxson, F. Hanna, and G. Koren, Evaluating the safety of St, 2009.

M. A. Mulot, Secrets d'une herboriste, 1987.

P. A. Murphy, S. E. Kern, F. Z. Stanczyk, and C. L. Westhoff, Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding, Contraception, vol.71, issue.6, pp.71-402, 2005.
DOI : 10.1016/j.contraception.2004.11.004

R. S. Obach, Inhibition of Human Cytochrome P450 Enzymes by Constituents of St, 2000.

Z. Ocak, M. Acar, E. Gunduz, M. Gunduz, K. Demircan et al., Effect of hypericin on the ADAMTS-9 and ADAMTS-8 gene expression in MCF7 breast cancer cells, European review for medical an pharmacological sciences, pp.1185-90, 2013.

G. I. Papakostas, C. M. Crawford, M. J. Scalia, and M. Fava, Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder, Neuropsychobiology, vol.56, issue.2-3, pp.132-137, 2007.
DOI : 10.1159/000115779

M. Philipp, R. Kohnen, and K. O. Hiller, Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicenter study of treatment for eight weeks, BMJ, pp.319-1534, 1999.

S. C. Piscitelli, A. H. Burstein, D. Chaitt, R. M. Alfaro, and J. Falloon, Indinavir concentrations and St John's wort, Indinavir concentrations and St John's Wort, pp.547-548, 2000.
DOI : 10.1016/S0140-6736(99)05712-8

J. N. Pradeep, Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology, Journal of Psychopharmacology, vol.15, issue.1, pp.47-54, 2001.

R. Rahimi, S. Nikfar, and M. Abdollahi, Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis, Progress in Neuropsychopharmacoly and Biological Psychiatry, pp.118-127, 2009.
DOI : 10.1016/j.pnpbp.2008.10.018

C. A. Roby, G. D. Anderson, E. Kantor, D. A. Dryer, and A. H. Burstein, St John's Wort: Effect on CYP3A4 activity, St John's Wort: effect on CYP3A4 activity, pp.451-457, 2000.
DOI : 10.1067/mcp.2000.106793

C. Röder, M. Schaefer, and S. Leucht, Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St John's Wort, 2004.

J. Ross, Matière médicale à usage clinique -120 plantes de la pharmacopée occidentale, pp.128-129, 2013.

E. Schrader, Equivalence of St John??s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mildmoderate depression, International Clinical Psychopharmacology, vol.15, issue.2, pp.61-68, 2000.
DOI : 10.1097/00004850-200015020-00001

E. Schrader, B. Meier, and A. Brattstrom, Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study, Human Psychopharmacology: Clinical and Experimental, vol.2, issue.3, pp.163-169, 1998.
DOI : 10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.0.CO;2-I

V. Schulz, Incidence and clinical relevance of the interactions and side effects of Hypericum preparations, Phytomedicine, vol.8, issue.2, pp.152-160, 2001.

U. I. Schwarz, H. Hanso, R. Oertel, S. Miehlke, E. Kuhlisch et al., Induction of Intestinal P-glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol, Clinical Pharmacology & Therapeutics, vol.150, issue.5, pp.81-669, 2007.
DOI : 10.1038/sj.clpt.6100191

A. L. Sharpley, C. L. Mcgavin, R. Whale, and P. Cowen, Antidepressant-like effect of Hypericum perforatum (St John's wort) on the sleep polysomnogram, Psychopharmacology, vol.139, issue.3, pp.286-293, 1998.
DOI : 10.1007/s002130050718

A. Singer, M. Wonneman, and W. E. Muller, Hyperforin a major antidepressant constituent of St John's Wort, inhibits serotonine uptake by elevating free intracellular Na+, 1999.

K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi et al., Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin, Clinical Pharmacology & Therapeutics, vol.70, issue.6, pp.518-524, 2001.
DOI : 10.1067/mcp.2001.120025

A. Szegedi, R. Kohnen, A. Dienel, and M. Kieser, Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine, BMJ, vol.330, issue.7490, pp.330-503, 2005.
DOI : 10.1136/bmj.38356.655266.82

S. John-'s, Wort decreases the bioavailability of R-and S-verapamil through induction of the first-pass metabolism, Clinical Pharmacology and Therapeutics, vol.75, issue.4, pp.298-309

K. Treiber, A. Singer, B. Henke, and W. E. Müller, Hyperforin activates nonselective cation channels (NSCCs), Hyperforin activates nonselective cation channels (NSCCs), pp.75-83, 2005.
DOI : 10.1038/sj.bjp.0706155

C. Ulbricht, E. Barrette, E. Basch, H. Boon, J. Conquer et al., A Thorough Analysis of the Safety Profile of St John's Wort by the Natural Standard Research Collaboration, Natural Medicine Journal, vol.2, issue.2, pp.1-11, 2010.

V. Hellemont and J. , Compendium de phytotherapie, Bruxelles, Ed Association pharmaceutique belge, pp.204-207, 1986.

. Vidal, Le guide des plantes qui soignent, édition Vidal, 2010.

Z. Wang, J. C. Gorski, M. A. Hamman, S. M. Huang, L. J. Lesko et al., The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity, Clinical Pharmacology & Therapeutics, vol.70, issue.4, pp.317-326, 2001.
DOI : 10.1016/S0009-9236(01)17221-8

M. Wenk, L. Todesco, and S. Krahenbuhl, Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females, pp.495-499, 2004.
DOI : 10.1016/S0009-9236(03)00187-5

D. Whitten, S. Myers, J. Hawrelak, and H. Wohlmuth, The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials, British Journal of Clinical Pharmacology, vol.67, issue.5, pp.62-512, 2006.
DOI : 10.1067/mcp.2002.124080

L. Will-shahab, S. Bauer, U. Kunter, I. Roots, and A. Brattström, St John???s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive, European Journal of Clinical Pharmacology, vol.62, issue.1, pp.287-94, 2009.
DOI : 10.1007/s00228-008-0587-2

H. Xu, K. M. Williams, W. S. Liauw, M. Murray, R. O. Day et al., Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide, British Journal of Pharmacology, vol.64, issue.7, pp.1579-1586, 2008.
DOI : 10.1038/sj.bjp.0707685

M. Zimmerman, J. H. Martinez, D. Young, I. Chelminski, and K. Dalrymple, Severity classification on the Hamilton depression rating scale, Severity classification on the Hamilton Depression Rating Scale, pp.384-388, 2013.
DOI : 10.1016/j.jad.2013.04.028